Literature DB >> 21725699

Infiltrating hepatocellular carcinoma: seeing the tree through the forest.

Aram Demirjian1, Peter Peng, Jean-Francois H Geschwind, David Cosgrove, Jacob Schutz, Ihab R Kamel, Timothy M Pawlik.   

Abstract

INTRODUCTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. It is traditionally difficult to cure, especially when discovered at later stages, making early diagnosis and intervention of paramount importance. HCC typically arises in the background of chronic liver disease and can have various morphologic appearances. One of the most difficult of these to recognize on early surveillance imaging is the infiltrative subtype, which can account for up to 13% of all HCC cases, and may be more closely associated with background hepatitis B infection. DISCUSSION: Certain imaging characteristics can provide vital clues, including differing signal intensity on the T1 and T2 sequences of magnetic resonance imaging (MRI) and the presence/appearance of portal vein thrombus. Owing to the diffuse and infiltrating properties of this tumor, surgical resection and transplantation are rarely if ever viable therapeutic options. Other forms of liver-directed therapy have been attempted with limited success, having minimal efficacy and high morbidity. To date, there is no data available to determine if the various HCC subtypes respond to systemic therapy differently, so this may be the most reasonable approach. Left untreated, observed patients commonly progress to hepatic failure fairly rapidly.
CONCLUSION: Infiltrative HCC can be extremely subtle, and therefore difficult to detect, especially in the background of cirrhosis. Providers caring for patients with hepatitis, chronic liver disease, and cirrhosis must be extremely vigilant in the evaluation of surveillance imaging in order to potentially discover this HCC subtype as early as possible and initiate a multidisciplinary treatment plan.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21725699      PMCID: PMC3580771          DOI: 10.1007/s11605-011-1614-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  39 in total

1.  Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma.

Authors:  Toshifumi Tada; Takashi Kumada; Hidenori Toyoda; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; Yasuhiro Hisanaga; Shusuke Kitabatake; Teiji Kuzuya; Koji Nonogaki; Junichi Shimizu; Akihiro Yamaguchi; Masatoshi Isogai; Yuji Kaneoka; Junji Washizu; Shinji Satomura
Journal:  Liver Int       Date:  2005-08       Impact factor: 5.828

Review 2.  Viral hepatitis and liver cancer: the case of hepatitis C.

Authors:  M Levrero
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

3.  Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma.

Authors:  Hisamitsu Miyaaki; Osamu Nakashima; Mina Kurogi; Katsumi Eguchi; Masamichi Kojiro
Journal:  J Gastroenterol       Date:  2007-12-25       Impact factor: 7.527

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study.

Authors:  Timothy M Pawlik; Ronnie T Poon; Eddie K Abdalla; Iwao Ikai; David M Nagorney; Jacques Belghiti; Reza Kianmanesh; Irene Oi-Lin Ng; Steven A Curley; Yoshio Yamaoka; Gregory Y Lauwers; Jean-Nicolas Vauthey
Journal:  Surgery       Date:  2005-04       Impact factor: 3.982

6.  Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments.

Authors:  Sun-Jung Myung; Jung-Hwan Yoon; Kang Mo Kim; Geum-Youn Gwak; Yoon Jun Kim; Ji-Won Yu; Jin Wook Chung; Hyo-Suk Lee
Journal:  Hepatogastroenterology       Date:  2006 Mar-Apr

7.  Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma.

Authors:  Timothy M Pawlik; Ronnie T Poon; Eddie K Abdalla; Daria Zorzi; Iwao Ikai; Steven A Curley; David M Nagorney; Jacques Belghiti; Irene Oi-Lin Ng; Yoshio Yamaoka; Gregory Y Lauwers; Jean-Nicolas Vauthey
Journal:  Arch Surg       Date:  2005-05

8.  Long interval between HCV infection and development of hepatocellular carcinoma.

Authors:  L Castells; V Vargas; A Gonzalez; J Esteban; R Esteban; J Guardia
Journal:  Liver       Date:  1995-06

9.  Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?

Authors:  Fabio Farinati; Dario Marino; Massimo De Giorgio; Anna Baldan; Maria Cantarini; Carmela Cursaro; Gianludovico Rapaccini; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Marco Zoli; Franco Borzio; Mauro Bernardi; Franco Trevisani
Journal:  Am J Gastroenterol       Date:  2006-03       Impact factor: 10.864

10.  Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3.

Authors:  X W Wang; K Forrester; H Yeh; M A Feitelson; J R Gu; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

View more
  30 in total

1.  Artificial neural network model for predicting 5-year mortality after surgery for hepatocellular carcinoma: a nationwide study.

Authors:  Hon-Yi Shi; King-Teh Lee; Jhi-Joung Wang; Ding-Ping Sun; Hao-Hsien Lee; Chong-Chi Chiu
Journal:  J Gastrointest Surg       Date:  2012-08-10       Impact factor: 3.452

2.  Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes.

Authors:  Peter J Kneuertz; Aram Demirjian; Amin Firoozmand; Celia Corona-Villalobos; Nikhil Bhagat; Joseph Herman; Andrew Cameron; Ahmet Gurakar; David Cosgrove; Michael A Choti; Jean-Francois H Geschwind; Ihab R Kamel; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2012-04-03       Impact factor: 5.344

3.  Association of Serum Ferritin with Diabetes and Alcohol in Patients with Non-Viral Liver Disease-Related Hepatocellular Carcinoma.

Authors:  Rohan C Siriwardana; Madunil A Niriella; Anuradha Dassanayake; Dileepa Ediriweera; Bhagya Gunetilleke; Thenuka Sivasundaram; Janaka de Silva
Journal:  Liver Cancer       Date:  2017-08-29       Impact factor: 11.740

4.  Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study.

Authors:  Qiang-Sheng Dai; Hong-Lin Gu; Sheng Ye; Yao-Jun Zhang; Xiao-Jun Lin; Wan Yee Lau; Zhen-Wei Peng; Min-Shan Chen
Journal:  Mol Clin Oncol       Date:  2014-08-18

5.  Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma.

Authors:  Neil Mehta; Nicholas Fidelman; Monika Sarkar; Francis Y Yao
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-17       Impact factor: 11.382

6.  Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization.

Authors:  Eun Sun Jang; Jung-Hwan Yoon; Jin Wook Chung; Eun Ju Cho; Su Jong Yu; Jeong-Hoon Lee; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-03       Impact factor: 4.553

7.  Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass.

Authors:  Stephen L Chan; Frankie Mo; Philip J Johnson; Deyond Y W Siu; Michael H M Chan; Wan Y Lau; Paul B S Lai; Christopher W K Lam; Winnie Yeo; Simon C H Yu
Journal:  HPB (Oxford)       Date:  2013-08-26       Impact factor: 3.647

8.  Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours.

Authors:  J Zhang; M N Mavros; D Cosgrove; K Hirose; J M Herman; S Smallwood-Massey; I Kamel; A Gurakar; R Anders; A Cameron; J F H Geschwind; T M Pawlik
Journal:  Curr Oncol       Date:  2013-04       Impact factor: 3.677

9.  Diffuse-Type Hepatoma: A Grave Prognostic Marker.

Authors:  Rohan C Siriwardana; Chandika A H Liyanage; Bhagya Gunetilleke; Madunil A Niriella; Janaka de Silva; Anuradha S Dassanayake; Subani P Jayatunge
Journal:  Gastrointest Tumors       Date:  2017-03-16

10.  The risk factors of early recurrence after hepatectomy in hepatocellular carcinoma.

Authors:  Soon-Keun Kwon; Sung-Su Yun; Hong-Jin Kim; Dong-Shik Lee
Journal:  Ann Surg Treat Res       Date:  2014-05-23       Impact factor: 1.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.